Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients
Accurate diagnosis of plasmacytoid urothelial carcinoma (PUC) is important given its poor prognosis and frequent presentation at high stage. We aim to assess the clinicopathological features, molecular aberrations, and follow-up data in a series of PUC cases from a single tertiary cancer center. Sev...
Gespeichert in:
Veröffentlicht in: | Human pathology 2019-08, Vol.90, p.27-36 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 36 |
---|---|
container_issue | |
container_start_page | 27 |
container_title | Human pathology |
container_volume | 90 |
creator | Perrino, Carmen M. Eble, John Kao, Chia-Sui Whaley, Rumeal D. Cheng, Liang Idrees, Mohammad Hashemi-Sadraei, Neda Monn, M. Francesa Kaimakliotis, Hristos Z. Bandali, Elhaam Grignon, David |
description | Accurate diagnosis of plasmacytoid urothelial carcinoma (PUC) is important given its poor prognosis and frequent presentation at high stage. We aim to assess the clinicopathological features, molecular aberrations, and follow-up data in a series of PUC cases from a single tertiary cancer center. Seventy-two urinary bladder, ureteral, and renal pelvic specimens with urothelial carcinoma with plasmacytoid differentiation were identified. Immunohistochemical stains were performed on 48 cases. Among urinary bladder origin markers, GATA3 was most sensitive (96%). Breast carcinoma markers (estrogen receptor, mammaglobin) were usually negative, but progesterone receptor stained 1 case (4%). Neuroendocrine markers CD56 and TTF-1 were each positive in 1 case (4% and 4%, respectively). Gastrointestinal adenocarcinoma marker CDX2 was positive in 4 cases (15%), but nuclear β-catenin was negative in all cases. CD138 was positive in 83% and E-cadherin expression was lost in 57% of cases. Fluorescence in situ hybridization using the UroVysion Bladder Cancer Kit and FGFR3 mutational analysis using polymerase chain reaction were performed on 15 cases; deletion of chromosome 9p21 was common (60%), and FGFR3 mutations were detected in 60% of cases (5 cases had both deletion 9p21 and FGFR3 mutations). Cases were divided into 3 morphologic groups: classic (29%), desmoplastic (35%), and pleomorphic (36%). The 3 morphologic subtypes had distinct survival outcomes (P = .083), with median survival for all patients 18 being months versus 10 months for the desmoplastic group.
•Urothelial carcinoma with plasmacytoid differentiation can be divided into 3 morphologic categories: (1) classic, (2) pleomorphic, and (3) desmoplastic.•Cases with plasmacytoid differentiation often present at a high stage, and within our dataset, cases assigned to the desmoplastic group had a worse outcome.•Urinary bladder origin immunohistochemical stains are sensitive for detecting the plasmacytoid variant.•Molecular aberrations present in conventional urothelial carcinoma are also present in the plasmacytoid variant. |
doi_str_mv | 10.1016/j.humpath.2019.04.012 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2232111605</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0046817719300772</els_id><sourcerecordid>2262664522</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-e1353133ff7c3d0ad1aa480849628bbe1ca578bc13c7cbb00f9bd2f00d91d1833</originalsourceid><addsrcrecordid>eNqFkT2P1DAQhi0E4paFnwCyREOT3Iwd54MGoRMcSCdBAbXl2A7xKokXf5y0_x6fdqGguWqa531nNA8hrxFqBGyvD_Wc16NKc80AhxqaGpA9ITsUnFU9H9hTsgNo2qrHrrsiL2I8ACCKRjwnVxxBNP3Q7cj990XFVelT8s5cGzdNOVqag0-zXZxaqFZBu82v6j1VNLrt12Irt8XkUk7Ob9Sta9787GLyerar0yWjNkNXv1idFxVoTNmcqJ9oO9BysLNbii_Js0kt0b66zD35-fnTj5sv1d232683H-8qLaBNlUUuOHI-TZ3mBpRBpZoe-mZoWT-OFrUSXT9q5LrT4wgwDaNhE4AZ0GDP-Z68O_ceg_-dbUxydVHbZVGb9TlKxjhDxBZEQd_-hx58Dlu5rlAta9tGFHpPxJnSwccY7CSPwa0qnCSCfBAjD_IiRj6IkdDIIqbk3lza87ha8y_110QBPpwBW95x72yQUZdXaWtcsDpJ490jK_4AC86jzQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2262664522</pqid></control><display><type>article</type><title>Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients</title><source>MEDLINE</source><source>ScienceDirect Freedom Collection (Elsevier)</source><creator>Perrino, Carmen M. ; Eble, John ; Kao, Chia-Sui ; Whaley, Rumeal D. ; Cheng, Liang ; Idrees, Mohammad ; Hashemi-Sadraei, Neda ; Monn, M. Francesa ; Kaimakliotis, Hristos Z. ; Bandali, Elhaam ; Grignon, David</creator><creatorcontrib>Perrino, Carmen M. ; Eble, John ; Kao, Chia-Sui ; Whaley, Rumeal D. ; Cheng, Liang ; Idrees, Mohammad ; Hashemi-Sadraei, Neda ; Monn, M. Francesa ; Kaimakliotis, Hristos Z. ; Bandali, Elhaam ; Grignon, David</creatorcontrib><description>Accurate diagnosis of plasmacytoid urothelial carcinoma (PUC) is important given its poor prognosis and frequent presentation at high stage. We aim to assess the clinicopathological features, molecular aberrations, and follow-up data in a series of PUC cases from a single tertiary cancer center. Seventy-two urinary bladder, ureteral, and renal pelvic specimens with urothelial carcinoma with plasmacytoid differentiation were identified. Immunohistochemical stains were performed on 48 cases. Among urinary bladder origin markers, GATA3 was most sensitive (96%). Breast carcinoma markers (estrogen receptor, mammaglobin) were usually negative, but progesterone receptor stained 1 case (4%). Neuroendocrine markers CD56 and TTF-1 were each positive in 1 case (4% and 4%, respectively). Gastrointestinal adenocarcinoma marker CDX2 was positive in 4 cases (15%), but nuclear β-catenin was negative in all cases. CD138 was positive in 83% and E-cadherin expression was lost in 57% of cases. Fluorescence in situ hybridization using the UroVysion Bladder Cancer Kit and FGFR3 mutational analysis using polymerase chain reaction were performed on 15 cases; deletion of chromosome 9p21 was common (60%), and FGFR3 mutations were detected in 60% of cases (5 cases had both deletion 9p21 and FGFR3 mutations). Cases were divided into 3 morphologic groups: classic (29%), desmoplastic (35%), and pleomorphic (36%). The 3 morphologic subtypes had distinct survival outcomes (P = .083), with median survival for all patients 18 being months versus 10 months for the desmoplastic group.
•Urothelial carcinoma with plasmacytoid differentiation can be divided into 3 morphologic categories: (1) classic, (2) pleomorphic, and (3) desmoplastic.•Cases with plasmacytoid differentiation often present at a high stage, and within our dataset, cases assigned to the desmoplastic group had a worse outcome.•Urinary bladder origin immunohistochemical stains are sensitive for detecting the plasmacytoid variant.•Molecular aberrations present in conventional urothelial carcinoma are also present in the plasmacytoid variant.</description><identifier>ISSN: 0046-8177</identifier><identifier>EISSN: 1532-8392</identifier><identifier>DOI: 10.1016/j.humpath.2019.04.012</identifier><identifier>PMID: 31054897</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - metabolism ; Bladder ; Bladder cancer ; Breast cancer ; Carcinoma, Transitional Cell - diagnosis ; Carcinoma, Transitional Cell - metabolism ; Carcinoma, Transitional Cell - pathology ; Diffuse ; Female ; Humans ; Immunohistochemistry ; Keratin ; Kidney Neoplasms - diagnosis ; Kidney Neoplasms - metabolism ; Kidney Neoplasms - pathology ; Male ; Medical prognosis ; Metastasis ; Middle Aged ; Morphology ; Plasmacytoid ; Retrospective Studies ; Signet ring ; Stains & staining ; Tumors ; Ureteral Neoplasms - diagnosis ; Ureteral Neoplasms - metabolism ; Ureteral Neoplasms - pathology ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - metabolism ; Urinary Bladder Neoplasms - pathology ; Urothelial carcinoma</subject><ispartof>Human pathology, 2019-08, Vol.90, p.27-36</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><rights>2019. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c506t-e1353133ff7c3d0ad1aa480849628bbe1ca578bc13c7cbb00f9bd2f00d91d1833</citedby><cites>FETCH-LOGICAL-c506t-e1353133ff7c3d0ad1aa480849628bbe1ca578bc13c7cbb00f9bd2f00d91d1833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.humpath.2019.04.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31054897$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perrino, Carmen M.</creatorcontrib><creatorcontrib>Eble, John</creatorcontrib><creatorcontrib>Kao, Chia-Sui</creatorcontrib><creatorcontrib>Whaley, Rumeal D.</creatorcontrib><creatorcontrib>Cheng, Liang</creatorcontrib><creatorcontrib>Idrees, Mohammad</creatorcontrib><creatorcontrib>Hashemi-Sadraei, Neda</creatorcontrib><creatorcontrib>Monn, M. Francesa</creatorcontrib><creatorcontrib>Kaimakliotis, Hristos Z.</creatorcontrib><creatorcontrib>Bandali, Elhaam</creatorcontrib><creatorcontrib>Grignon, David</creatorcontrib><title>Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients</title><title>Human pathology</title><addtitle>Hum Pathol</addtitle><description>Accurate diagnosis of plasmacytoid urothelial carcinoma (PUC) is important given its poor prognosis and frequent presentation at high stage. We aim to assess the clinicopathological features, molecular aberrations, and follow-up data in a series of PUC cases from a single tertiary cancer center. Seventy-two urinary bladder, ureteral, and renal pelvic specimens with urothelial carcinoma with plasmacytoid differentiation were identified. Immunohistochemical stains were performed on 48 cases. Among urinary bladder origin markers, GATA3 was most sensitive (96%). Breast carcinoma markers (estrogen receptor, mammaglobin) were usually negative, but progesterone receptor stained 1 case (4%). Neuroendocrine markers CD56 and TTF-1 were each positive in 1 case (4% and 4%, respectively). Gastrointestinal adenocarcinoma marker CDX2 was positive in 4 cases (15%), but nuclear β-catenin was negative in all cases. CD138 was positive in 83% and E-cadherin expression was lost in 57% of cases. Fluorescence in situ hybridization using the UroVysion Bladder Cancer Kit and FGFR3 mutational analysis using polymerase chain reaction were performed on 15 cases; deletion of chromosome 9p21 was common (60%), and FGFR3 mutations were detected in 60% of cases (5 cases had both deletion 9p21 and FGFR3 mutations). Cases were divided into 3 morphologic groups: classic (29%), desmoplastic (35%), and pleomorphic (36%). The 3 morphologic subtypes had distinct survival outcomes (P = .083), with median survival for all patients 18 being months versus 10 months for the desmoplastic group.
•Urothelial carcinoma with plasmacytoid differentiation can be divided into 3 morphologic categories: (1) classic, (2) pleomorphic, and (3) desmoplastic.•Cases with plasmacytoid differentiation often present at a high stage, and within our dataset, cases assigned to the desmoplastic group had a worse outcome.•Urinary bladder origin immunohistochemical stains are sensitive for detecting the plasmacytoid variant.•Molecular aberrations present in conventional urothelial carcinoma are also present in the plasmacytoid variant.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Bladder</subject><subject>Bladder cancer</subject><subject>Breast cancer</subject><subject>Carcinoma, Transitional Cell - diagnosis</subject><subject>Carcinoma, Transitional Cell - metabolism</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Diffuse</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Keratin</subject><subject>Kidney Neoplasms - diagnosis</subject><subject>Kidney Neoplasms - metabolism</subject><subject>Kidney Neoplasms - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Morphology</subject><subject>Plasmacytoid</subject><subject>Retrospective Studies</subject><subject>Signet ring</subject><subject>Stains & staining</subject><subject>Tumors</subject><subject>Ureteral Neoplasms - diagnosis</subject><subject>Ureteral Neoplasms - metabolism</subject><subject>Ureteral Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Urinary Bladder Neoplasms - metabolism</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urothelial carcinoma</subject><issn>0046-8177</issn><issn>1532-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkT2P1DAQhi0E4paFnwCyREOT3Iwd54MGoRMcSCdBAbXl2A7xKokXf5y0_x6fdqGguWqa531nNA8hrxFqBGyvD_Wc16NKc80AhxqaGpA9ITsUnFU9H9hTsgNo2qrHrrsiL2I8ACCKRjwnVxxBNP3Q7cj990XFVelT8s5cGzdNOVqag0-zXZxaqFZBu82v6j1VNLrt12Irt8XkUk7Ob9Sta9787GLyerar0yWjNkNXv1idFxVoTNmcqJ9oO9BysLNbii_Js0kt0b66zD35-fnTj5sv1d232683H-8qLaBNlUUuOHI-TZ3mBpRBpZoe-mZoWT-OFrUSXT9q5LrT4wgwDaNhE4AZ0GDP-Z68O_ceg_-dbUxydVHbZVGb9TlKxjhDxBZEQd_-hx58Dlu5rlAta9tGFHpPxJnSwccY7CSPwa0qnCSCfBAjD_IiRj6IkdDIIqbk3lza87ha8y_110QBPpwBW95x72yQUZdXaWtcsDpJ490jK_4AC86jzQ</recordid><startdate>201908</startdate><enddate>201908</enddate><creator>Perrino, Carmen M.</creator><creator>Eble, John</creator><creator>Kao, Chia-Sui</creator><creator>Whaley, Rumeal D.</creator><creator>Cheng, Liang</creator><creator>Idrees, Mohammad</creator><creator>Hashemi-Sadraei, Neda</creator><creator>Monn, M. Francesa</creator><creator>Kaimakliotis, Hristos Z.</creator><creator>Bandali, Elhaam</creator><creator>Grignon, David</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201908</creationdate><title>Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients</title><author>Perrino, Carmen M. ; Eble, John ; Kao, Chia-Sui ; Whaley, Rumeal D. ; Cheng, Liang ; Idrees, Mohammad ; Hashemi-Sadraei, Neda ; Monn, M. Francesa ; Kaimakliotis, Hristos Z. ; Bandali, Elhaam ; Grignon, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-e1353133ff7c3d0ad1aa480849628bbe1ca578bc13c7cbb00f9bd2f00d91d1833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Bladder</topic><topic>Bladder cancer</topic><topic>Breast cancer</topic><topic>Carcinoma, Transitional Cell - diagnosis</topic><topic>Carcinoma, Transitional Cell - metabolism</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Diffuse</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Keratin</topic><topic>Kidney Neoplasms - diagnosis</topic><topic>Kidney Neoplasms - metabolism</topic><topic>Kidney Neoplasms - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Morphology</topic><topic>Plasmacytoid</topic><topic>Retrospective Studies</topic><topic>Signet ring</topic><topic>Stains & staining</topic><topic>Tumors</topic><topic>Ureteral Neoplasms - diagnosis</topic><topic>Ureteral Neoplasms - metabolism</topic><topic>Ureteral Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Urinary Bladder Neoplasms - metabolism</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urothelial carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perrino, Carmen M.</creatorcontrib><creatorcontrib>Eble, John</creatorcontrib><creatorcontrib>Kao, Chia-Sui</creatorcontrib><creatorcontrib>Whaley, Rumeal D.</creatorcontrib><creatorcontrib>Cheng, Liang</creatorcontrib><creatorcontrib>Idrees, Mohammad</creatorcontrib><creatorcontrib>Hashemi-Sadraei, Neda</creatorcontrib><creatorcontrib>Monn, M. Francesa</creatorcontrib><creatorcontrib>Kaimakliotis, Hristos Z.</creatorcontrib><creatorcontrib>Bandali, Elhaam</creatorcontrib><creatorcontrib>Grignon, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Human pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perrino, Carmen M.</au><au>Eble, John</au><au>Kao, Chia-Sui</au><au>Whaley, Rumeal D.</au><au>Cheng, Liang</au><au>Idrees, Mohammad</au><au>Hashemi-Sadraei, Neda</au><au>Monn, M. Francesa</au><au>Kaimakliotis, Hristos Z.</au><au>Bandali, Elhaam</au><au>Grignon, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients</atitle><jtitle>Human pathology</jtitle><addtitle>Hum Pathol</addtitle><date>2019-08</date><risdate>2019</risdate><volume>90</volume><spage>27</spage><epage>36</epage><pages>27-36</pages><issn>0046-8177</issn><eissn>1532-8392</eissn><abstract>Accurate diagnosis of plasmacytoid urothelial carcinoma (PUC) is important given its poor prognosis and frequent presentation at high stage. We aim to assess the clinicopathological features, molecular aberrations, and follow-up data in a series of PUC cases from a single tertiary cancer center. Seventy-two urinary bladder, ureteral, and renal pelvic specimens with urothelial carcinoma with plasmacytoid differentiation were identified. Immunohistochemical stains were performed on 48 cases. Among urinary bladder origin markers, GATA3 was most sensitive (96%). Breast carcinoma markers (estrogen receptor, mammaglobin) were usually negative, but progesterone receptor stained 1 case (4%). Neuroendocrine markers CD56 and TTF-1 were each positive in 1 case (4% and 4%, respectively). Gastrointestinal adenocarcinoma marker CDX2 was positive in 4 cases (15%), but nuclear β-catenin was negative in all cases. CD138 was positive in 83% and E-cadherin expression was lost in 57% of cases. Fluorescence in situ hybridization using the UroVysion Bladder Cancer Kit and FGFR3 mutational analysis using polymerase chain reaction were performed on 15 cases; deletion of chromosome 9p21 was common (60%), and FGFR3 mutations were detected in 60% of cases (5 cases had both deletion 9p21 and FGFR3 mutations). Cases were divided into 3 morphologic groups: classic (29%), desmoplastic (35%), and pleomorphic (36%). The 3 morphologic subtypes had distinct survival outcomes (P = .083), with median survival for all patients 18 being months versus 10 months for the desmoplastic group.
•Urothelial carcinoma with plasmacytoid differentiation can be divided into 3 morphologic categories: (1) classic, (2) pleomorphic, and (3) desmoplastic.•Cases with plasmacytoid differentiation often present at a high stage, and within our dataset, cases assigned to the desmoplastic group had a worse outcome.•Urinary bladder origin immunohistochemical stains are sensitive for detecting the plasmacytoid variant.•Molecular aberrations present in conventional urothelial carcinoma are also present in the plasmacytoid variant.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31054897</pmid><doi>10.1016/j.humpath.2019.04.012</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0046-8177 |
ispartof | Human pathology, 2019-08, Vol.90, p.27-36 |
issn | 0046-8177 1532-8392 |
language | eng |
recordid | cdi_proquest_miscellaneous_2232111605 |
source | MEDLINE; ScienceDirect Freedom Collection (Elsevier) |
subjects | Adult Aged Aged, 80 and over Biomarkers, Tumor - metabolism Bladder Bladder cancer Breast cancer Carcinoma, Transitional Cell - diagnosis Carcinoma, Transitional Cell - metabolism Carcinoma, Transitional Cell - pathology Diffuse Female Humans Immunohistochemistry Keratin Kidney Neoplasms - diagnosis Kidney Neoplasms - metabolism Kidney Neoplasms - pathology Male Medical prognosis Metastasis Middle Aged Morphology Plasmacytoid Retrospective Studies Signet ring Stains & staining Tumors Ureteral Neoplasms - diagnosis Ureteral Neoplasms - metabolism Ureteral Neoplasms - pathology Urinary Bladder Neoplasms - diagnosis Urinary Bladder Neoplasms - metabolism Urinary Bladder Neoplasms - pathology Urothelial carcinoma |
title | Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A09%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasmacytoid/diffuse%20urothelial%20carcinoma:%20a%20single-institution%20immunohistochemical%20and%20molecular%20study%20of%2069%20patients&rft.jtitle=Human%20pathology&rft.au=Perrino,%20Carmen%20M.&rft.date=2019-08&rft.volume=90&rft.spage=27&rft.epage=36&rft.pages=27-36&rft.issn=0046-8177&rft.eissn=1532-8392&rft_id=info:doi/10.1016/j.humpath.2019.04.012&rft_dat=%3Cproquest_cross%3E2262664522%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2262664522&rft_id=info:pmid/31054897&rft_els_id=S0046817719300772&rfr_iscdi=true |